These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24063617)

  • 1. Mouse monoclonal antibody towards e1 specific epitope blocks viral entry and intracellular viral replication in vitro.
    Tabll AA; Moustafa RI; El Abd YS; Bader El Din NG; El-Shenawy R; Yousef H; Hussein M; Dawood RM; Omran MH; El-Awady MK
    J Immunoassay Immunochem; 2014; 35(1):60-73. PubMed ID: 24063617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro neutralization of HCV by goat antibodies against peptides encompassing regions downstream of HVR-1 of E2 glycoprotein.
    Tabll AA; Atef K; Bader El Din NG; El Abd YS; Salem A; Sayed AA; Dawood RM; Omran MH; El-Awady MK
    J Immunoassay Immunochem; 2014; 35(1):12-25. PubMed ID: 24063613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2.
    El Abd YS; Tabll AA; El Din NG; Hosny Ael-D; Moustafa RI; El-Shenawy R; Atef K; El-Awady MK
    Virol J; 2011 Aug; 8():391. PubMed ID: 21819575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
    Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
    Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
    Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA
    J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
    Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mice Antibody Response to Conserved Nonadjuvanted Multiple Antigenic Peptides Derived from E1/E2 Regions of Hepatitis C Virus.
    Abdelhafez TH; Bader El Din NG; Tabll AA; Mashaly MM; Dawood RM; Yassin NA; El-Awady MK
    Viral Immunol; 2017 Jun; 30(5):359-365. PubMed ID: 28402196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
    Bose M; Mullick R; Das S; Das S; Karande AA
    Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
    Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
    Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
    Keck ZY; Op De Beeck A; Hadlock KG; Xia J; Li TK; Dubuisson J; Foung SK
    J Virol; 2004 Sep; 78(17):9224-32. PubMed ID: 15308717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
    Grollo L; Torresi J; Drummer H; Zeng W; Williamson N; Jackson DC
    Antivir Ther; 2006; 11(8):1005-14. PubMed ID: 17302370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
    Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
    J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference.
    Sautto G; Mancini N; Diotti RA; Solforosi L; Clementi M; Burioni R
    Antiviral Res; 2012 Oct; 96(1):82-9. PubMed ID: 22898087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
    Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-neutralizing antibodies to hepatitis C virus.
    Wahid A; Dubuisson J
    J Viral Hepat; 2013 Jun; 20(6):369-76. PubMed ID: 23647953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes.
    Das S; Behera P; Shewale DJ; Bodele J; Das S; Karande AA
    Arch Virol; 2024 Apr; 169(5):112. PubMed ID: 38683226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
    Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
    J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein.
    Duan H; Kachko A; Zhong L; Struble E; Pandey S; Yan H; Harman C; Virata-Theimer ML; Deng L; Zhao Z; Major M; Feinstone S; Zhang P
    J Virol; 2012 Dec; 86(23):12686-94. PubMed ID: 22973024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.
    Keck ZY; Sung VM; Perkins S; Rowe J; Paul S; Liang TJ; Lai MM; Foung SK
    J Virol; 2004 Jul; 78(13):7257-63. PubMed ID: 15194801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.